Key facts
- This page summarizes Dong Kim's Form 4 filing for UroGen Pharma Ltd. (URGN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Sep 2024, 13:50.
Dong Kim - 09 Sep 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- URGN
- Reported as of
- 09 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Sep 2024, 13:50:15 UTC
- Prior SEC filing
- 02 Feb 2024
- Next SEC filing
- 27 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason D. Smith, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dong Kim filed Form 4 for UroGen Pharma Ltd. (URGN) on 12 Sep 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
URGN
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +2,500
- Change %
- +7.1%
- Price
- Shares after
- 37,753
- Date
- 09 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
URGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,500
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 5,000
- Date
- 09 Sep 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 2,500
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Footnote F2
The reporting person was granted RSUs on September 7, 2023 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.